Products

Cytokeratin 17 – MMab

IHC of CK17 on an FFPE Cervical Carcinoma Tissue

IHC of CK 17 on an FFPE Cervical Cancer Tissue

Specification Sheets
Safety Data Sheet
Intended UseFor In Vitro Diagnostic Use
Summary and ExplanationCytokeratin 17 (CK 17) is a Type I cytokeratin with a MW of 46 kD found sometimes in association with Cytokeratin 7. Cytokeratin 17 is found in nail beds, hair follicles, sebaceous glands, and other epidermal appendages. Mutations in the gene encoding this protein lead to Jackson-Lawler type Pachyonychia Congenita and Steatocystoma Multiplex.Cytokeratin 17 antibody has been used to distinguish immature Cervical Squamous Metaplasia from High Grade Cervical Intraepithelial Neoplasia (CIN III). Anti-CK 17 also labels myoepithelial cells in the benign breast tissue. CK 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK 5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact
with basal cytokeratins including anti-CK 17. The histologic differentiation of
ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK 17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
Antibody TypeMouse MonoclonalCloneBSB-33
IsotypeIgG2a/KReactivityParaffin, Frozen
LocalizationCytoplasmicControlSkin, Testis, Breast, Cervix, Cervical Carcinoma, Bladder TCC
PresentationCytokeratin 17 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Availability
Catalog No.Antibody TypeDilutionVolume/QTY
BSB 2726PredilutedReady-To-Use3.0 ml
BSB 2727PredilutedReady-To-Use7.0 ml
BSB 2728PredilutedReady-To-Use15.0 ml
BSB 2729Concentrated1:25-1:1000.1 ml
BSB 2730Concentrated1:25-1:1000.5 ml
BSB 2731Concentrated1:25-1:1001.0 ml
BSB 2732Control Slides5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.

Related products

Skip to content